Journal Updates
eMediNexus Coverage from: 
Better survival with modified FOLFIRINOX regimen for patients with pancreatic cancer
eMediNexus,  26 December 2018
remove_red_eye 584 Views
#Gastroenterology #Hematology #Oncology #Pathology and Lab Medicine #Pharmacist

0 Read Comments                

In a 24-week study published December 20, 2018 in the New England Journal of Medicine, adjuvant therapy with a modified FOLFIRINOX regimen (oxaliplatin [85 mg/m2], irinotecan [180 mg/m2, reduced to 150 mg/m2 after a protocol-specified safety analysis], leucovorin [400 mg/m2], and fluorouracil [2400 mg/m2] every 2 weeks) led to significantly longer survival than gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) among patients with resected pancreatic cancer. At a median follow-up
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!